Studies Find Targeting Anhedonia and Exercise Outperform Standard Therapy for Depression and Anxiety

A pair of research findings has generated widespread media coverage in early 2026: a randomized controlled trial showing that targeting anhedonia — the inability to feel pleasure — produces better outcomes than conventional therapy, and an updated Cochrane review confirming that exercise performs comparably to antidepressants and talk therapy for depression. The implications are significant: roughly 21 million American adults experienced a major depressive episode in 2020 [1], and standard treatments fail a substantial minority. But the gap between what these studies actually show and what the headlines claim deserves close scrutiny.

What the Anhedonia Studies Found

In April 2026, researchers at Southern Methodist University and UCLA published results from a randomized controlled trial of 98 adults with severe anhedonia, depression, and anxiety in JAMA Network Open [2]. The study compared Positive Affect Treatment (PAT) — a 15-session psychotherapy targeting the brain's reward system — against a conventional therapy focused on reducing negative emotions like sadness and anxiety (Negative Affect Treatment, or NAT).

PAT produced greater improvement in overall clinical status than NAT, with a between-group effect size of Cohen's d = 0.27 for clinical status and d = 0.40 for reward anticipation-motivation [3]. These gains persisted at one-month follow-up (d = 0.21) [3]. The trial enrolled participants who were 66.3% female with a mean age of 32.8 years, all meeting criteria for severely low positive affect with moderate-to-severe, functionally impairing depression or anxiety [3].

Separately, a pilot randomized controlled trial of Augmented Depression Therapy (ADepT) — developed in the UK and published in eClinicalMedicine in 2023 — compared 20 sessions of ADepT against CBT in 82 adults with moderate-to-severe depression and anhedonic features [4]. ADepT showed between-group effect sizes of d = 0.23 for depression and d = 0.27 for wellbeing compared to CBT [4]. Within-group improvements were large (Cohen's d > 1.10 for depression, wellbeing, and anhedonia), and at 18 months, ADepT had greater than 80% probability of cost-effectiveness [4].

Source: PAT (Meuret et al. 2026, JAMA Network Open); ADepT (Dunn et al. 2023, eClinicalMedicine); Cochrane Review 2026

Data as of Apr 26, 2026CSV

What These Effect Sizes Actually Mean

Context matters. A Cohen's d of 0.27 is conventionally classified as a "small" effect. The FDA does not use Cohen's d as its threshold for clinical significance in antidepressant trials; instead, it has historically looked for a minimum 2-point difference on the Hamilton Depression Rating Scale, though even this threshold is debated [5]. The between-group advantages of PAT and ADepT over their comparators — while statistically significant — are modest by any standard.

The within-group effect sizes are more impressive. ADepT's d > 1.10 represents a large effect, meaning patients improved substantially from their baseline [4]. But within-group effects are inherently inflated by regression to the mean and natural symptom fluctuation. The critical question — how much better are these treatments than existing options — is answered by the between-group comparisons, which are small.

"It's not enough to take away the bad," said Alicia Meuret, co-lead researcher on the PAT study at SMU. "Treatment needs to ask: Is this activity meaningful to you? Will it give you joy or a sense of accomplishment?" [2]

How PAT and ADepT Differ from Standard Therapy

Standard CBT for depression focuses on identifying and correcting negative thought patterns — catastrophizing, all-or-nothing thinking, personalization. The theory is that fixing distorted cognition reduces depressive symptoms. PAT takes a fundamentally different approach by targeting the reward system directly [2].

PAT works through exercises designed to re-engage patients with rewarding activities, redirect attention toward positive experiences, and build practices including gratitude, savoring, and loving-kindness meditation [2]. The treatment was developed over more than a decade by Michelle Craske at UCLA and Alicia Meuret and Thomas Ritz at SMU [2].

ADepT, developed through the UK's NHS system, combines elements of behavioral activation with a focus on building positive emotions and wellbeing alongside traditional depression treatment [4].

A notable finding from the PAT trial: patients improved on measures of both positive and negative emotion, despite the treatment never directly addressing negativity [3]. This suggests that repairing the reward system may have downstream effects on the negative emotional processing that conventional therapy targets head-on.

The Exercise Evidence: Large but Fragile

The exercise-depression literature is far larger. Over 236,000 academic papers have been published on exercise and depression therapy since 2011, peaking at 33,084 in 2024 [6].

Source: OpenAlex

Data as of Jan 1, 2026CSV

A 2024 network meta-analysis in the BMJ, covering 218 studies and 14,170 participants, found exercise was linked to moderate improvement in depressive symptoms (standardized mean difference of -0.61) and meaningful but smaller gains for anxiety (SMD = -0.47) [7]. An umbrella review in the British Journal of Sports Medicine reported similar magnitudes, concluding exercise was comparable to or exceeded traditional pharmacological and psychological interventions [8].

But the 2026 Cochrane review — widely considered the gold standard for evidence synthesis — injects caution. Across 73 studies involving at least 4,985 adults, exercise showed a moderate pooled effect versus no treatment (SMD = -0.62) [9]. However, when the analysis was restricted to six high-quality trials with 464 participants, the effect shrank to -0.18 and became statistically insignificant [9]. Against active treatments — psychotherapy and antidepressants — the review found no significant difference, but acknowledged this conclusion rested on "a few small studies" [9].

Source: PAT (Meuret et al. 2026, JAMA Network Open); ADepT (Dunn et al. 2023, eClinicalMedicine); Cochrane Review 2026

Data as of Apr 26, 2026CSV

Follow-Up and Durability

The PAT trial's follow-up window was only one month [2]. For a condition with relapse rates between 50% and 80% over a lifetime, one month tells us little about whether the treatment holds. ADepT's pilot data is more encouraging: improvements were "largely sustained over one year follow-up" with no evidence of harms, and the advantage over CBT was preserved at 18 months [4]. But this was a pilot trial of 82 people at a single site, not a definitive test.

For exercise, the Cochrane review found a small effect favoring exercise at long-term follow-up across eight trials with 377 participants (SMD = -0.33), though this evidence was rated low certainty [9]. The practical challenge is adherence: exercise interventions have higher dropout rates than pharmacological treatments because the intervention is physically demanding and requires sustained behavioral change [10].

Who Was Studied — and Who Was Left Out

The PAT trial enrolled adults with severe anhedonia but moderate-to-severe depression [3]. The ADepT trial recruited from NHS waiting lists — patients with current major depressive episodes scoring 10 or above on the PHQ-9 [4]. Neither trial specifically targeted treatment-resistant depression, patients with active suicidality requiring immediate intervention, or those with complex psychiatric comorbidities like bipolar disorder or psychotic features.

This matters because treatment-resistant depression — affecting roughly 30% of patients who try antidepressants [11] — is where the need for new approaches is most acute, and also where exercise and novel psychotherapies have the least evidence. The populations studied in these trials are the ones most likely to respond to any active treatment, making the comparison against standard care look more favorable.

Source: OpenAlex

Data as of Jan 1, 2026CSV

The Anhedonia Problem: Why Standard Treatments Underperform

Anhedonia — defined as a diminished capacity to experience pleasure, interest, or motivation — affects an estimated 35% to 70% of patients with major depressive disorder [12]. By some measures, up to 90% of people with major depression experience some degree of reduced positive affect [2]. It is a core diagnostic criterion for MDD and a robust predictor of poor treatment response, prolonged illness, and suicide risk [12].

Source: Translational Psychiatry 2025; IJPN 2026

Data as of Apr 26, 2026CSV

Standard SSRIs work primarily on serotonin pathways. They are effective at reducing negative mood and anxiety but have limited impact on the dopamine-mediated reward circuits that underlie anhedonia [13]. This is why many patients on antidepressants report feeling "flattened" — the lows are less severe, but the capacity for joy does not return. CBT similarly focuses on reducing negative cognition rather than building positive emotional capacity.

Higher anhedonia severity is associated with greater impairment while working, poorer quality of life, and higher direct medical costs [14]. The economic case for targeting anhedonia directly is plausible, even if the clinical evidence is early-stage.

Independent Expert Assessment

Not everyone involved in these studies shares the enthusiasm of the headlines. Prof. Michael Bloomfield of University College London, responding to the exercise meta-analysis, warned against "claiming exercise superior to existing treatments," identified bias risks across many studies, and stressed that "severe depression requires comprehensive approaches" [15].

Dr. Paul Keedwell of the Royal College of Psychiatrists noted that many exercise studies had small sample sizes and lacked real-world conditions, and emphasized that depressed individuals often find exercise genuinely challenging to initiate [15].

A 2024 commentary in the Journal of Physical Activity and Health made a sharper critique: "The evidence is clear, exercise is not better than antidepressants or therapy: it is crucial to communicate science honestly" [16]. The authors argued that media coverage systematically overclaims the benefits of exercise relative to established treatments, inflating results from heterogeneous, often poorly blinded studies.

For the anhedonia-targeted therapies, the evidence base is even thinner. The PAT trial had 98 participants. The ADepT trial had 82 at a single center. Neither has been independently replicated. These are proof-of-concept studies, not practice-changing evidence — a distinction that press releases from the participating universities did not always make clear.

The Steelman Case for Standard Treatment

For specific patient populations, SSRIs and CBT remain the strongest evidence-based options. Patients with severe depression — particularly those with active suicidal ideation — need treatments with rapid onset. SSRIs, while imperfect, have decades of efficacy data across large populations and multiple independent trials [5]. Generic fluoxetine costs approximately $163 per course of treatment, is available at any pharmacy, and requires no specialized therapist training [17].

CBT has the most robust evidence base of any psychotherapy for depression, with hundreds of randomized trials and multiple independent replications [5]. For patients with comorbid anxiety disorders, PTSD, or OCD, CBT variants with specific protocols exist and are well-validated.

Exercise cannot safely replace medication for patients in acute psychiatric crisis. A patient experiencing suicidal ideation with a plan needs immediate pharmacological and possibly inpatient intervention — not a gym membership. For patients with chronic, recurrent depression who have responded to SSRIs in the past, switching to an unproven anhedonia-targeted therapy would be clinically premature.

Cost and Access: The Practical Reality

Proponents of exercise interventions emphasize their low cost and broad accessibility. This is true for unsupervised walking or jogging, but structured, supervised exercise programs — the kind with the strongest evidence — require trained professionals, appropriate facilities, and patient transportation [10]. In rural areas with provider shortages, these may be no more accessible than a CBT therapist.

PAT and ADepT require specialized training that most therapists do not currently have. PAT involves 15 weekly sessions of a specific protocol developed over a decade at two research universities [2]. Scaling this to community mental health settings, Federally Qualified Health Centers, or telehealth platforms would require significant infrastructure investment.

By contrast, generic SSRIs are prescribed by primary care physicians, require no specialized mental health training to initiate, and work whether the patient lives in Manhattan or rural Montana. This accessibility advantage should not be dismissed when evaluating the comparative value of novel treatments.

The Replication Question

The exercise-depression literature has a history of overclaimed findings. Prior headlines declaring exercise "as effective as" or "better than" antidepressants have repeatedly been tempered by higher-quality analyses. The 2026 Cochrane review showed the effect collapsing from moderate (d = 0.62) to negligible (d = 0.18) when restricted to low-bias studies [9]. This pattern — large effects in weak studies, small or null effects in strong ones — is a hallmark of inflated findings across psychology and exercise science.

The anhedonia-targeted therapies face a different version of the same problem. With only two small trials from the labs that developed the interventions, we do not know whether PAT or ADepT will perform as well in the hands of community therapists, in diverse patient populations, or when evaluated by researchers without a professional stake in the outcome. Pre-registration status and independent replication are the benchmarks that separate preliminary findings from clinical evidence — and neither threshold has been met.

Prof. Jonathan Roiser of UCL noted the inherent challenge: exercise studies cannot be double-blinded — participants know whether they are exercising [15]. This introduces expectancy effects that can inflate results relative to pharmacological trials where blinding is standard.

What Comes Next

The research trajectory is clear. Academic publications on anhedonia and depression treatment have surged, with 35,218 papers published since 2011 and a peak of 4,840 in 2025 [6]. The field is investing heavily in understanding reward processing, and larger, multi-site trials of PAT and ADepT are likely forthcoming.

For now, the responsible interpretation is this: anhedonia-targeted therapies and exercise are promising additions to the treatment toolkit for depression and anxiety. They address real gaps — the reward system deficit that SSRIs ignore, and the physical inactivity that compounds depressive symptoms. But neither is ready to displace established treatments, especially for patients with severe, treatment-resistant, or complex depression. The headlines have outrun the evidence.